Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation : a retrospective analysis of the EBMT chronic malignancies working party

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/228617

Lähdeviite

Scheid , C , de Wreede , L , van Biezen , A , Koenecke , C , Gohring , G , Volin , L , Maertens , J , Finke , J , Passweg , J , Beelen , D , Cornelissen , J J , Itälä-Remes , M , Chevallier , P , Russell , N , Petersen , E , Milpied , N , Espiga , C R , Peniket , A , Sierra , J , Mufti , G , Crawley , C , Veelken , J H , Ljungman , P , Cahn , J Y , Alessandrino , E P , de Witte , T , Robin , M & Kroeger , N 2017 , ' Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation : a retrospective analysis of the EBMT chronic malignancies working party ' , Bone Marrow Transplantation , vol. 52 , no. 11 , pp. 1519-1525 . https://doi.org/10.1038/bmt.2017.171

Julkaisun nimi: Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation : a retrospective analysis of the EBMT chronic malignancies working party
Tekijä: Scheid, C.; de Wreede, L.; van Biezen, A.; Koenecke, C.; Gohring, G.; Volin, L.; Maertens, J.; Finke, J.; Passweg, J.; Beelen, D.; Cornelissen, J. J.; Itälä-Remes, M.; Chevallier, P.; Russell, N.; Petersen, E.; Milpied, N.; Espiga, C. Richard; Peniket, A.; Sierra, J.; Mufti, G.; Crawley, C.; Veelken, J. H.; Ljungman, P.; Cahn, J. Y.; Alessandrino, E. P.; de Witte, T.; Robin, M.; Kroeger, N.
Tekijän organisaatio: Clinicum
Department of Oncology
HUS Comprehensive Cancer Center
Päiväys: 2017-11
Kieli: eng
Sivumäärä: 7
Kuuluu julkaisusarjaan: Bone Marrow Transplantation
ISSN: 0268-3369
DOI-tunniste: https://doi.org/10.1038/bmt.2017.171
URI: http://hdl.handle.net/10138/228617
Tiivistelmä: The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (P <0.001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high 7.9 months, very high 5.5 months (P <0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant.
Avainsanat: PROGNOSTIC SCORING SYSTEM
BONE-MARROW-TRANSPLANTATION
ACUTE MYELOID-LEUKEMIA
MONOSOMAL KARYOTYPE
MDS
CLASSIFICATION
CYTOGENETICS
OUTCOMES
SOCIETY
3122 Cancers
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by_nc_nd
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
bmt2017171.pdf 792.9KB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot